TRIB2 and cancer: Like TRIB1, TRIB2 represents a still poorly characterized mediator of proliferative signalling pathways, and TRIB2 modulators (such as conformation‐biased inhibitors) may be good therapeutic agents in multiple cancers especially in the context of drug resistance.